All In Biotech

Drug Trial Radar · NCT06617416

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Consolidation Therapy of AK104 Versus Sugemalimab in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent or Sequential Chemoradiotherapy

Last checked: Nov 20, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

560

Planned (sponsor's estimate)

Start

Nov 12, 2024

Primary completion

Oct 28, 2026

Study completion Dec 30, 2028

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Sep 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares the efficacy and safety of AK104 versus Sugemalimab as consolidation therapy in patients with unresectable, locally advanced NSCLC who have not progressed following concurrent or sequential chemoradiotherapy.

Conditions

  • NSCLC (Non-small Cell Lung Cancer)

Interventions

  • Cadonilimab (AK104)Drug

    AK104 ivgtt Q3W

  • SugemalimabDrug

    1200mg Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by INVTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital of Shandong First Medical University

    Jinan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.